Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Nitric Oxide ; 4(4): 412-22, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10944426

ABSTRACT

Acute lung injury (ALI) is associated with diminished surfactant activity and pulmonary hypertension. NONOates are soluble NO donors which release NO in solution. Intratracheal NONOates reduce pulmonary hypertension and improve oxygenation in ALI. We hypothesized that the pharmacologic properties of NO donors would be unaltered after surfactant admixture in vitro and that aerosolized NONOate activity would be enhanced by surfactant pretreatment in vivo. NO donors were added to saline or surfactant and analyzed for nitrite/nitrate production and aortic ring vasodilation. Surfactant did not alter nitrate/nitrite production or aortic ring vasodilation. A porcine model of ALI with pulmonary hypertension was produced using intravenous oleic acid. Animals were assigned to Surfactant-Saline, Surfactant-NONOate, Saline-Saline, or Saline-NONOate groups. Saline or surfactant was instilled into the trachea, followed by gas exchange, pulmonary function, and hemodynamic measurements. NONOate or saline was then aerosolized, and additional data were collected. Oxygenation was improved in the Surfactant-NONOate group, while pulmonary hypertension was selectively reduced in both NONOate groups. Aerosolized NONOate following surfactant pretreatment improves oxygenation and reduces pulmonary hypertension in ALI.


Subject(s)
Hypertension, Pulmonary/drug therapy , Lung/physiopathology , Nitric Oxide Donors/pharmacology , Penicillamine/analogs & derivatives , Pulmonary Gas Exchange/drug effects , Pulmonary Surfactants/pharmacology , Respiratory Distress Syndrome/drug therapy , Amino Acids, Diamino/pharmacology , Animals , Aorta/drug effects , Aorta/physiology , Disease Models, Animal , Drug Synergism , Hemodynamics/drug effects , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/pathology , Hypertension, Pulmonary/physiopathology , In Vitro Techniques , Lung/drug effects , Lung/pathology , Male , Methemoglobin/metabolism , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Nitric Oxide/pharmacology , Oleic Acid , Penicillamine/pharmacology , Random Allocation , Rats , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/pathology , Respiratory Distress Syndrome/physiopathology , S-Nitroso-N-Acetylpenicillamine , Swine
2.
Am J Respir Crit Care Med ; 158(5 Pt 1): 1536-42, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9817705

ABSTRACT

Acute respiratory distress syndrome (ARDS) is a major cause of morbidity and mortality in critically ill patients. The associated ventilation/perfusion mismatch and pulmonary hypertension are amenable to treatment with inhaled nitric oxide (NO) gas. Compounds formed by reacting NO with various nucleophiles (NONOates) release NO spontaneously and induce vasodilation. Intratracheally administered NONOates result in selective reduction in pulmonary hypertension. We hypothesized that a nebulized NONOate would improve oxygenation and reduce pulmonary vascular resistance in oleic acid-induced acute lung injury and pulmonary hypertension. Pigs underwent catheterization of the pulmonary artery, left atrium, and right atrium, and a flow probe was positioned around the pulmonary artery. Acute lung injury and pulmonary hypertension were induced with intravenous oleic acid. Animals were randomly assigned to receive either nebulized saline or the NONOate 2-(dimethylamino)ethylputreanine/NO (DMAEP/NO). Hemodynamic, gas exchange, pulmonary function, methemoglobin, and nitrite/nitrate measurements were obtained for 60 min. Animals in the DMAEP/NO group had improvement in PaO2 as compared with control animals (from 139 +/- 19 mm Hg to 180 +/- 19 mm Hg in the DMAEP/NO group [n = 6]; and from 144 +/- 6 mm Hg to 150 +/- 9 mm Hg in the saline group [n = 6], p < 0.05). After aerosol treatment, animals in the DMAEP/NO group had a greater reduction in pulmonary vascular resistance index (PVRI) than did control animals (from 81 +/- 17 dyne. s/cm5/kg to 34 +/- 8 dyne. s/cm5/kg; and from 104 +/- 16 dyne. s/cm5/kg to 64 +/- 11 dyne. sec/cm5/ kg in the saline group at 60 min, p < 0.05). There were no differences between the groups in systemic vascular resistance index (SVRI), cardiac index (CI), methemoglobin, nitrite/nitrate, or lung pathology scores. We conclude that DMAEP/NO improves oxygenation and has selective pulmonary vasodilating properties without causing significant systemic toxicity in this porcine model of acute lung injury.


Subject(s)
Hypertension, Pulmonary/drug therapy , Nitric Oxide Donors/therapeutic use , Oxygen Consumption/drug effects , Respiratory Distress Syndrome/drug therapy , Administration, Inhalation , Aerosols , Amino Acids, Diamino/administration & dosage , Amino Acids, Diamino/therapeutic use , Animals , Cardiac Catheterization , Cardiac Output/drug effects , Catheterization, Swan-Ganz , Disease Models, Animal , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/pathology , Injections, Intravenous , Lung/blood supply , Lung/drug effects , Lung/pathology , Male , Methemoglobin/analysis , Nebulizers and Vaporizers , Nitrates/analysis , Nitric Oxide/administration & dosage , Nitric Oxide/therapeutic use , Nitric Oxide Donors/administration & dosage , Nitrites/analysis , Oleic Acid/administration & dosage , Oleic Acid/adverse effects , Pulmonary Gas Exchange/drug effects , Random Allocation , Respiratory Distress Syndrome/chemically induced , Respiratory Distress Syndrome/pathology , Solubility , Swine , Vascular Resistance/drug effects , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic use , Ventilation-Perfusion Ratio/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL